Accenture (NYSE: ACN) has named eight companies as finalists in the Accenture HealthTech Innovation Challenge, which brings together leading-edge startups with prominent health companies to tackle some of North America's greatest health challenges.

Attracting more than 2,600 startup applicants in the past five years, the Accenture HealthTech Innovation Challenge supports finding innovative approaches and solutions to help create better healthcare access, experiences and ultimately outcomes for all people.

Clinicians at Bolton NHS Foundation Trust have dramatically reduced patient waiting times, decreased hospital length of stay and improved patient safety after developing an electronic acute medical list solution to manage patient referrals. 

The configuration was initially set-up to track referrals and admissions to the Acute Medicine Unit (AMU) Team from multiple sources.

The new Clinerion patent underpins any medical EHR database infrastructure that incorporates a hybrid model of cloud-and-local server node installations at individual hospitals, as well as any method for search of patient cohort care metrics across such a platform. This allows real-time search at each individual hospital across the entire network at once, returning aggregate metrics from the entire network.

Exscientia, a clinical-stage, artificial intelligence (AI)-driven pharmatech company, today announced that Bristol Myers Squibb has elected to in-license an immune-modulating drug candidate created by Exscientia. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology.

Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow and blockages to assist physician decision-making and provide the best pathway for treatment.

Siemens Healthineers presents its second pathway for its AI-Pathway Companion(1) at the Healthcare Information and Management Systems Society Global Health Conference 2021 (HIMSS 21). This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process(2).

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the introduction of two new Philips HealthSuite solutions that are secure, cloud-based and intended to break down barriers across patient care in a scalable, cost-effective model.